Connect with us

Biochemistry Instruments and Reagents

Automated biochemistry analyzers are gaining traction

Modern biochemistry has a solid foundation due to traditional manual laboratory techniques. But as technology has developed, testing procedures have changed; many tests may be carried out in automated labs with the help of innovative equipment like chemical analyzers.

Biochemistry labs are becoming increasingly automated, with sophisticated instrumentation capable of completing hundreds to thousands of tests each hour, as is the case in other areas of laboratory. Two out of every three older persons in India have a chronic disease, and biochemistry is likely to continue to be crucial to patient care, according to the first Longitudinal Ageing Study in India published by the Union Ministry of Family and Health Welfare.

Biochemistry analyzers have been evolving at a rapid pace, with fully automated equipment already on the market. These analyzers are capable of recognizing sample and reagent bottles, tube sampling, cap piercing, automatic re-run, and dilution, among other things. One of the primary industry trends is value-based outsourcing, in which laboratory testing is outsourced to clinical reference laboratories. Clinical laboratories have collaborations with small hospitals that lack basic infrastructure for clinical diagnostics. Hospitals outsource the patients to these labs for undergoing various diagnostic tests.

Due to considerable technological breakthroughs and expanding healthcare industry demands, the use of clinical chemistry analyzers has rapidly expanded over the past few decades. Clinical chemistry provides precise diagnostic information, and generally concentrates on the examination of bodily internal fluids. Modern clinical chemistry has a solid foundation due to traditional manual laboratory techniques. But as technology has developed, testing procedures have changed; many tests may be carried out in automated labs with the help of innovative equipment like chemical analyzers.

The market for biochemistry analyzers is expected to rise more quickly due to novel technological developments, enhanced production methods, and the introduction of innovative software.

In recent years, the market has shifted from a fee-for-service to a value-based-care paradigm, resulting in the outsourcing of laboratory services to diagnostic vendors. In the future years, the shift from hospital outsourcing to reference laboratories will be a major driver for the biochemistry analyzers market.

Indian market dynamics
In 2022, the Indian biochemistry instruments and reagents market is estimated at ₹2699 crore, with reagents continuing to dominate at ₹2220 crore at 83-percent market share. This is an 11-percent increase by value and a 17-percent increase by quantity, over 2021. Momentum in sales is expected to be maintained for the next five years.

The floor-standing analyzers are estimated at ₹154 crore and 1075 units; bench-top analyzers at ₹140 crore and 3435 units; and semi-automated analyzers at ₹185 crore and 30,990 units. As expected, the floor instruments are largely on rentals, and semi-automated instruments are all procured. The size of the market has been calculated on assigning a monetary value to all the instruments installed, whether placed or sold.

Transasia continues to be a clear leader in this segment. Roche, Beckman Coulter, Siemens, OCD, and Abbott are the other leading brands for reagents. In the fully automated instruments segment, Mindray, OCD, and Roche have an aggressive presence.

Huge orders were placed by the government in 2022, and the trend continues in 2023. Orders were awarded by HLL, GeM, and AIIMS, and West Bengal Medical Services Corporation Ltd., Tamil Nadu Medical Services Corporation Ltd., and Kerala Medical Services Corporation among others. In 2023 too, tenders have already been invited by the governments of Assam (Ministry of Defence), and Bharat Petroleum Corporation Limited. The Prison Department, Gujarat; Armed Forces Medical Services, Rajasthan; Ministry of Defence, Punjab; Departments Of Health and Family Welfare, Madhya Pradesh, Odisha, Karnataka, and Rajasthan have invited tenders for small quantities. Transasia was recently awarded an order for 814 units of semi-automated instruments under NHM from the Assam government. ABC Diagnostics Pvt. Ltd. has also been awarded an order for reagents from Kerala Medical Services Corporation. Indian Air Force, Gujarat, has invited a tender too and Transasia, Athena, and Ark Diagnostic System have been shortlisted.

Leading players*
FA SA Reagents
Tier 1 Transasia Transasia Transasia, Roche, Agappe,  Beckman Coulter, Siemens, OCD, and  Abbott (and Mindray)
Tier 2 Mindray, OCD, POCT, Agappe,
and Roche
Mindray and Rapid Randox, Accurex, Diasys, and GenWorks
Tier 3 GenWorks, Biosystems, Beckman Coulter, Abbott, Thermo Fisher, Siemens, and CPC Agappe, URIT, CPC, Biosystems, Thermo Fisher, Accurex, Tulip, Microlab, Beacon, Robonik, and regional brands URIT, Biosystems, Fuji, Rapid, Beacon, Rapocon, AGD, CPC, Fuji, POCT, Biogene, Biolab, Ark Diagnostics, and local brands
Others Trivitron, Sysmex, Tulip, Biosystems, Accurex (Dirui),  AGD,  Rapid, and Randox
*Vendors are placed in different tiers on the basis of their sales contribution to the overall revenues of the Indian biochemistry instruments and reagents market.

ADI Media Research

Technological advancements and emerging trends
Thomas John
Managing Director,

Biochemistry is the application of chemistry to the study of biological processes at the cellular and molecular levels, for the analysis of cells, blood, and other body fluids for their chemical, biochemical, and hormonal components, using samples of serum, plasma, and urine.

Biochemical analysis was based on colorimetry, where absorbance was measured to assess the concentration of the solution. The monochromator, used in the earlier colorimeters, was colored glass.

Subsequently, filter-based photometry was employed, whereby the interference filter replaced the colored glass in the analyzers, for precise wavelength selection and better accuracy.

Grating photometry is the present tool for automation, precision, and accuracy. Dependable results are guaranteed with this for special parameters as well as for the routine tests like lipids, LFT, RFT, etc.

There are multiple advanced features available in the grating photometry system, which is giving an upper hand as compared to normal interference photometry.

  • Provides a linear dispersion of wavelength;
  • Reduces the absorption effects;
  • More numbers of perfect wavelengths;
  • Long lifespan;
  • Minimal maintenance.

Clinical chemistry has shown a steady double-digit growth trend for the last two decades. In the clinical chemistry automation bench-top analysis, FAA has grown by 25 percent. With the expansion of chain lab and profile testing, the opportunity for this particular product has become immense. Along with the normal trend, the post-Covid effect is going to be an additional opportunity for this market.

Agappe, as a leading Indian IVD company, is providing a range of fully automatic biochemistry analyzers like Mispa CXL Pro Plus, Mispa Nano Plus, and Biolis 30i for different kinds of workload customers. The targeted customer base is mid-size labs, the customers who are the users of multiple semi-automation. The tendency and the opportunities of the chain labs are huge. The chain labs are evolving to use mid-size analyzers in their branches. The users of fully automated analyzers, who are the users of normal interference photometry, are evolving to grating photometry. Along with this, current semi-auto users are upgrading to the use of fully auto analyzers as overall lab testing has increased.

Agappe offers fully automated clinical chemistry analyzers at best affordable price, along with best quality.

Chain labs as SRL, Pathkind, and Redcliffe Noida were some of the buyers for fully automated biochemistry analyzers in 2022

Global market dynamics
The global biochemistry analyzers market was worth USD 12.61 billion in the year 2021. The market is projected to grow at a CAGR of 7 percent, earning revenues of around USD 18.63 billion by the end of 2028. The global market is booming because the worldwide clinical analyzers market is being driven by technical breakthroughs, such as the StaRRsed Inversa automated erythrocyte sedimentation rate (ESR) analyzer, as well as increased awareness about personal health and the benefits associated with these devices. Furthermore, constant efforts by public and private healthcare organizations to improve data dependability drive demand for clinical analyzers.

Product insights. Reagents dominated the market with the maximum share in the category of product in 2022. The industry’s large supply of reagents, which is provided to satisfy a range of clinical demands, is projected to be the cause of the sizeable market share. Lipids, enzymes, specific proteins, substrates, electrolytes, and other substances stand as the main ingredients of these reagents. They are essential to achieve accurate results in analytical procedures. Reagents are also regarded as very economical, and excellent in terms of linearity, precision, and sensitivity, which assures little alterations in performance. The benefits listed above are likely to be very influential in encouraging clinicians to employ reagents for precise diagnosis.

Test insights. The prevalence of lifestyle-related diseases, including obesity and other metabolic abnormalities, is on the rise, and in 2022, basic metabolic panel (BMP) enjoyed a monopoly in the test market. The growing importance and awareness of point-of-care (POCT) testing is a crucial factor in the sector share. BMP is a group of examinations that provide medical examiners with clinical information about problems caused by chemical imbalances in the body.

This test’s universal acceptance and accompanying benefits have increased its market share over time. Additionally, BMP is being utilized and accepted in a growing number of applications, such as newborn screening, which makes it easier to find metabolic and genetic problems that are present at birth. It has the capacity to identify 30 hereditary metabolic diseases in a single dried filter paper blood spot, according to a study that was published in NCBI.

Technological advances. CTCs can be efficiently separated from whole blood, using next-generation microfluidic technology, for example. These devices require few chemicals and samples and offer a short analysis turnaround time. Because of technological advancements in POCT devices, clinical biochemistry analyzers have gained in popularity. The increased global burden of chronic diseases, particularly in developed countries, has resulted in the widespread use of portable biochemistry analyzers. As a result, increased demand for portable or bench-top biochemistry analyzers is expected to result in lower healthcare costs and faster diagnosis and treatment, boosting the global biochemistry analyzers market.

Advancements in biochemistry analyzers and reagents
Bhupendra Chaudhary
Sr. President – Sales & Marketing,
Transasia Bio-Medicals Ltd.

The ivd industry has witnessed a fast-evolving series of technological advancements in biochemistry instrumentation. Starting from a simple colorimeter, and a semi-automated analyzer, today’s fully automated biochemistry analyzers boast of electronic calibration, robotic pipetting/sample mixing, and automated maintenance processes for helping laboratories offer accurate results.

Some of the high-end biochemistry analyzers offer:

Operational excellence
Fully automatic biochemistry analyzers form the backbone of any clinical chain laboratory that churns out huge sample workload. Thus, to have the ability to test a large number of samples accurately in lowest turnaround time (TAT) is the need of the hour. For this, autoloader is the best suitable option, as it offers continuous loading facility, thereby making it a true walk-away system.

Further, reflex testing can help labs and assist clinicians with interpretation of results, and aid in further disease management in patients, by configuring paired tests in the event of high or low results seamlessly, without any additional effort, for the technologist. Reflex testing may prevent the need for additional specimen procurement from the patient.

Pre-analytical risk mitigation
For accurate reporting of any parameter in the shortest time period, it is mandatory to avoid pre-analytical errors. In small labs or even large-chain labs, the major concern is sample handling, starting from collection till testing, due to long transport time and distance. This may cause sample deterioration and eventually wrong reporting. Hence, serum indices identification is a crucial function of any FAA for accurate reporting.

Clots in sample either may lead to inaccurate results or may block sample probe; reducing the MTBF(mean time between failure); thus with clot detection both these problems can be avoided. Clot-detection feature helps users to identify samples with small clots of fibrins in it, thus ensuring accurate results.

Service excellence
Internet-of-Things (IoT) is one of the futuristic must-have features in FAA. Automation, combined with AI and cloud-based technologies, reduces downtime of the instrument dramatically by offering remote service facility.

Clinical excellence
Advancement in reagent portfolio is also in much demand where one-thirds of the test workload of any typical laboratory comprises glucose and creatinine. Glucose test can be upgraded with hexokinase method, which has superiority over conventional GOD-POD method in case of linearity and creatinine with enzymatic method, which has better stability than conventional Jaffes method.

Challenge. High-volume biochemistry analyzers may be purchased only by major hospitals and reference labs with healthy capital budgets. The majority of small labs, medical offices, and solo practitioners may not be able to purchase a large or exceptionally large-sized analyzer with no capital expenses. As a result, the high fixed-cost requirements limit the growth of the clinical chemistry analyzers market. Both developed and developing countries are currently suffering from a serious shortage of laboratory workers. This is primarily due to an increasing patient base, retiring technicians, and financially strapped colleges abandoning clinical lab programs. Consequently, there is a global mismatch between supply and demand for pathologists and lab technicians, which is anticipated to restrain the market growth.

Research update
Investigators from the Institute of Scientific and Industrial Research at Osaka University, together with Hiroshima Institute of Technology, have announced the discovery of a new protein that allows an organism to conduct an initial and essential step in converting amino acid residues on a cross-linked polypeptide into an enzyme cofactor. This research may lead to a better understanding of the biochemistry underlying catalysis in cells.

Every living cell is constantly pulsing with an array of biochemical reactions. The rates of these reactions are controlled by special proteins called enzymes, which catalyze specific processes that would otherwise take much longer. A number of enzymes require specialized molecules called cofactors, which can help shuttle electrons back and forth during oxidation-reduction reactions. But these cofactors themselves must be produced by the organisms, and often require the assistance of previously existing proteins.

Now, a team of scientists at Osaka University has identified a novel protein called QhpG that is essential for the biogenesis of the enzyme cofactor cysteine tryptophylquinone (CTQ). By analyzing the mass of the reaction products and determining their crystal structure, they were able to deduce the catalytic function of QhpG, which is adding two hydroxyl groups to a specific tryptophan residue within an active-site subunit QhpC of quinoheme protein amine dehydrogenase, the bacterial enzyme catalyzing the oxidation of various primary amines. The resulting dihydroxylated tryptophan and an adjacent cysteine residue are finally converted to cofactor CTQ.

Automation and technology – Two arms of biochemistry
Shobhit Jain
Sr. Manager, Product – Clinical Chemistry, Urinalysis, Marketing Events, and Branding,
Sysmex India Pvt. Ltd.

Indian in vitro diagnostic (IVD) industry is growing at a phenomenal pace with excellent potential to emerge as a global manufacturing hub in medical devices. Especially, after success of the government’s Make in India initiative, many multinational companies have started planning to initiate manufacturing in India. After China, Japan, and South Korea, India is the fourth-largest market in IVD diagnostics in Asia.

Biochemistry segment continues to dominate IVD market with largest contribution in the growth of Indian IVD market. Indian biochemistry market in 2022 is estimated at ₹2400 crore, in which reagent segment accounts for 83 percent and instrument segment 17 percent. High prevalence of chronic diseases, increasing use of point-of-care (POC) diagnostics, rising awareness, acceptance of personalized medicine, and companion diagnostics are the major growth factors. Covid pandemic and resurgence of Covid also played a pivotal role in growth of biochemistry, which increased the demand for special parameters like LDH/ferritin/D-Dimer/CRP and reduction in manual or human interventions.

The journey of biochemistry started with very basic measurement systems like colorimeter and flame photometer, which were taken over by semi-automatic analyzer and batch analyzers in the next decade. Furthermore, with technological advancement (automatic on-board hemolysis for HbA1c, permanent cuvettes, onboard laundry and cooling, clot detection, bidirectional interfacing, Westgard QC reporting systems), integration (modular platform), tools for pre-analytical, analytical, and post-analytical, the future of biochemistry lies in automation and total lab automation (TLA).

Due to other socio-economic factors like growing population, increase in health awareness in Tier-II and Tier-III cities, increase in medical tourism, resulting in increase in sample load, there is a growing need for automation, which enables fast, cost-efficient, and high-quality testing. In addition to that, labs are also expanding their business by expanding menu, opening new branches, and joining hands with existing market leaders, creating good demand for automation. To conclude, from the small-sizes to high-end laboratories and from private to public sector hospitals, there is a high demand for automation, and it will be exponentially growing in future.

However, the action of QhpG is somewhat unusual compared with other protein-modifying enzymes in that it reacts with the tryptophan residue on the QhC triply cross-linked by another enzyme QhpD in a process called post-translation modification. Tryptophan, which naturally contains rings with conjugated bonds, needs the fewest changes to become a quinone cofactor.

The proteins were obtained by introducing plasmids with the corresponding genes into Escherichia coli (E. coli) bacteria and made into crystals. X-ray diffraction data of the crystal can determine the QhpG protein structure. The team then used computer software to simulate the docking of the target molecules, the triply cross-linked polypeptide QhpC, based on the crystal structure they found for QhpG. The two post-translational modifications of QhpC are successively carried out in the modification enzyme complex QhpD-QhpG.

“Our findings can be applied to development of novel bioactive peptides, using enzymes that modify amino acids,” senior author Toshihide Okajima says. Some of these applications include creating new enzymes for the bioremediation of toxic chemicals.

Disruptive innovations in clinical biochemistry
Examples of disruptive innovation include the use of dry chemistry reagents in chemistry analyzers in the core laboratory and POCT. The latter is defined as an investigation done close to the patient at the time of the consultation. These are usually performed by a nurse, without the need for a laboratory technologist, with instant availability of results to make immediate informed decisions about patient care. There is a growing list of POCT, including pregnancy tests, measuring blood sugar level by glucometers, cardiac biomarker tests, and the list continues to grow. POCT has the typical features of a disruptive innovation, including being cheaper, quicker, and easier to perform, but with less accuracy compared to a standard laboratory test. Handheld analyzers for testing whole blood are another example of a disruptive technology that can be used for POCT, even at home.

Clinical chemistry
Subhash Shinde
Assistant General Manager,
Beacon Diagnostics Pvt. Ltd. (A Beacon Group Company)

Clinical chemistry accounts for the largest volumes of tests in laboratory medicine. It is also the basis of the majority of clinical decisions that are impacted by laboratory results.

The Covid-19 pandemic caused significant hurdles for the healthcare sector. But when the Covid-19 infection spread, more clinical chemistry testing for SARS-CoV-2 virus was carried out. Tests, including procalcitonin, albumin, lactate dehydrogenase, and the C-reactive protein (CRP), were used to assess organ involvement and disease severity, and to estimate the probability of morbidity and mortality. During the pandemic, it also assisted in keeping track of the affected people’s general health. Therefore, the Covid-19 pandemic increased the use of these tests, which contributed significantly to the market’s expansion and had a favorable effect on the market’s growth.

Now in the post pandemic area, clinical chemistry will be driven by the rising incidence of infectious and chronic diseases, such as cancer and diabetes, which create a need for prompt and precise diagnosis. Factors, such as unhealthy diet, the rising geriatric population, sedentary lifestyles, and a lack of exercise also contributes in this market growth. Technological advancements, rising disposable incomes, driving up demand for improved diagnostics, and the life-threatening nature of diseases and disorders will also play major role in progress of this market segment. Rising patient load and frequent readmissions are important forces for hospitals to hold substantial share in this segment.

Use of reagents in preclinical research to track the diseases and medication development are opening gates for novel utility approach of clinical chemistry. Moreover, reagents are beneficial for numerous scientific studies that aim to comprehend the mode of action and interactions between various product cycle stages.

On the front of technology, fully automated clinical chemistry testing is becoming popular due to increased testing volume and quicker processing times provided by them. Additionally, with advanced processing, automated clinical chemistry testing boosts user protection from biohazards and decreases the possibility of cross-contamination.

Ever since its inception, Beacon has remained as one of the forefront players in this segment and continues to offer customer focus solutions for both reagents and instruments.

The switch from manual labor-intensive laboratories into fully automated chemistry analyzers is another example of successful disruptive thinking. We are now incorporating even more advanced technology in the chemistry core laboratory, including mobile general-purpose dual-arm robots that mark a new horizon for automations. These robots can perform certain repetitive tasks faster, cheaper, and more accurately than humans. They can be employed to perform sophisticated multiple-step tests like the enzyme-linked immunosorbent assay (ELISA).

Disruptive innovations include the use of matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry as a clinical tool for pathogen identification. Another emerging disruptive innovation, jointly developed by Google and Novartis, includes a glucose-sensing electrode with telemetry so that glucose levels are monitored from the tears of the eye and transmitted to remote devices. The use of disposable electronics is an interesting example of a disruptive innovation in POCT. An example of this is the digital pregnancy test, “FirstResponse™ Pregnancy Pro,” which is a wireless technology-enabled pregnancy test that connects via Bluetooth to a smartphone. Another example is the “rHEALTH” sensor, which is a small portable device that is able to perform a large number of laboratory tests using one drop of blood.

Molecular diagnostics – Today and tomorrow….
Dr Rajas V Warke
Director – Molecular Biology & Virology,
HiMedia Labs Pvt.Ltd.

Molecular-based diagnostics has emerged as the technology to achieve the goal of faster and sensitive diagnosis with minimal complexities. The demand for this confirmatory procedure is growing higher because of its better accuracy, specificity, and speed. Currently, the focus is molecular detection of infectious disease, followed by oncology and genetic testing and neonatal testing. In recent years, major viral and bacterial outbreaks globally (e.g., Covid-19, influenza, Ebola) have been detected using molecular tests.

The global molecular diagnostics market size was valued at USD 37.04 billion in 2021. The business potential of molecular tests is broadly divided into three segments: instruments and service, PCR/RT-PCR reagents, and extraction kits. The reagents and kits account for the largest segment in molecular diagnostics due to their recurrent usage, followed by instrument, software, and services domains.

The merger of molecular tests and PoC devices is ushering in a new era of self-testing diagnostics, and patient awareness about faster diagnostics. Furthermore, automation of molecular laboratories to detect bacterial, fungal, viral pathogens, along with genetic tests, is anticipated to boost the molecular instrument market growth.

Newer molecular test avenues include sequencing technologies for the molecular diagnostics market that include DNA sequencing processes and emerging NGS technologies, which are linked to drug discovery, novel drug development, and personalized medicine.

On the basis of application, the molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, blood screening, transplant medicine, hematology, cardiovascular diseases, neurological and infectious diseases (Covid-19, hepatitis MTB, influenza, and others).

Molecular microbiology is rapidly growing as it can both identify and characterize a microorganism based on drug susceptibility, thus allowing the clinician to administer the appropriate drug and its dosage in a much shorter time.

Molecular pathology and diagnostics are revolutionizing the diagnostic laboratory by providing a new level of detail to clinicians and medical professionals.

Some concerns for the industry like the high instrumentation cost and their maintenance, along with stringent regulations for the approval of molecular diagnostics products, are projected to challenge the molecular diagnostics market in the forecast period of 2023–2029. The improvement in access, technical expertise, and post-Covid availability of cost-effective resources are anticipated to drive the molecular diagnostics market growth.

Disruptive innovations also extend into inventing robotic devices for automated blood drawing. These devices have the potential to replace standard blood drawing in clinical laboratories, and thus save money, labor, and time. It also has the ability to improve the workflow in hospitals and private clinics, especially those associated with POCT equipment to provide quick results.

Considerations for purchasing a biochemistry analyzer
When choosing a clinical analyzer, research the instrument’s throughput capability (which can reach up to 10,000 combined ISE and colorimetric tests per hour), testing speed, and test menu to be sure it is a good fit for your laboratory. Will a STAT mode or random-access capability be required? Is batch, random, or continuous analysis preferred? Consider if additional testing will be offered by the lab in the future to ensure the system offers the required capabilities. Remember that a higher-end instrument that uses less expensive reagents may prove to be more cost-effective over its lifetime. Additional factors include sample handling, the unit’s footprint, and its ability to work with microvolumes, a valuable parameter in neonatal units. Laboratories handling thousands of tests per hour will require bar-code handling and data management software.

Growing need for automation in biochemistry
Dhiren Trambadia
Vice President,
Trivitron Healthcare

Biochemistry analyzers are in-vitro diagnostic devices, used extensively in clinical laboratories, hospitals & clinics to measure biochemical analytes in body fluids, blood plasma, serum, cerebrospinal fluids, urine, etc. It benefits the doctors to diagnose through testing of kidney profiles, liver function test profiles, diabetic profiles, lipid profiles, electrolyte, coagulation, etc. Current biochemistry analyzers are based on selective absorption of light by a substance that is the spectrophotometry and based on Beer’s Lambart’s law. They have wireless connectivity to ensure better sharing of patient data, especially for labs with LIS.

While choosing a biochemistry analyzer, it is important for the pathologist to take into account if assay automation is required, the specificity of the reagents, and measurement-accuracy levels. It is also important to consider sample workload at the same time.

The semi-automated biochemistry analyzer operates using optical measuring techniques, similar to the operation of fully automated biochemistry analyzers. To enhance the routine workflow, Trivitron Healthcare offers ultra-modern semi-automated biochemistry analyzers – Labmate NXT – next-generation clinical chemistry and immuno-turbidimetry analyser and Labmate Plus+, an advanced clinical chemistry coagulation immuno-turbidimetry analyzer. With user-defined and customized report format, the labs/hospitals/pathologists can upload their logo digital signature to generate letter head-like report format and deliver timely reports. These analyzers are compatible almost with every external printer, making it suitable for low- to medium-workload-size laboratories.

With fully automated chemistry analyzers, the entire process from sample addition to result is done automatically. Automation in analyzers eliminates the potential of manual errors, such as volumetric pipetting, calculation, and transcription of results. Trivitron’s Nanolab 200 is a fully automated bench-top analyzer with highest capacity for onboard samples and reagents (40 and 80), with throughput of 200 tests/hour. It comes with continuous sample- and reagent-loading facility. Nanolab 500 is also a fully automated biochemistry analyzer, with throughput up to 300 Photometric tests/hour, and 480 tests/hour with optional ISE (Na/K/CL).

Trivitron offers complete clinical chemistry solution with analyzers, along with its reagents, which have long shelf life and ready-to-use pack sizes produced in the state-of-the-art manufacturing facility under the Make in India initiative.

Advances in biochemistry analyzers
Advances in biochemistry analyzers will be concurrent with the development of new assays, further improving patient care. Manufacturers are customizing analyzers for use in smaller laboratories as also for use in very-high volume situations, such as in large hospitals or in the field. As software capabilities continue to develop, biochemistry analyzers will be able to offer increased testing speed and degree of automation.

Copyright © 2024 Medical Buyer

error: Content is protected !!